Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery

NCT: NCT06221020 · RECRUITING

NCT IDNCT06221020
StatusRECRUITING
Start Date2023-12-12
Completion2026-11-30
SponsorChang Gung Memorial Hospital (OTHER)
First posted
Last updated

Brief Summary

The goal of this observational study is to evaluate the effectiveness and impact of Enhanced Recovery After Surgery (ERAS) on patients with pituitary gland tumors.

Frequently Asked Questions

What is To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery?

To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery is a clinical trial registered under NCT06221020. Current status: RECRUITING.

What is the status of NCT06221020?

The current status of NCT06221020 (To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery) is: RECRUITING.

When did To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery start?

To Assess the Impact of theERAS Consensus on Patients With Endoscopic Pituitary Tumor Surgery started on 2023-12-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑